EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Surface Wipe Sampling of Hazardous Medicinal Products: A European Interlaboratory Comparison Study

Roland B van den Berg iD, Ewelina Korczowska, Mónica S F Santos iD, Maria Francisca Portilha-Cunha iD, Ana R L Ribeiro iD, Lucie Bláhová, Luděk Bláha iD, Claudia Vom Eyser, Jochen Tuerk iD, Richard C J M van Rossen, Erik B Wilms iD, Mirjam Crul iD

Drug Testing and Analysis · 2025

DOI: 10.1002/dta.3902 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Roland B van den Berg und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Hazardous Substances. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Society of Oncology Pharmacy (ESOP), Foundation for Science and Technology (FCT), FCT/MCTES (PIDDAC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Workplace monitoring of hazardous medicinal products (HMPs) using surface wipe sampling is becoming common practice in many European hospitals and pharmacies. However, no independent quality control is available to validate wiping procedures and analytical methods. This study aimed to conduct a Europe‐wide interlaboratory comparison (ILC) program to independently and blindly assess laboratory performance and variability in HMP detection. Four European laboratories participated in the study. Six HMPs—cyclophosphamide, etoposide, gemcitabine, ifosfamide, methotrexate, and paclitaxel—were prepared at four concentrations (5000, 2000, 200, and 20 ng/mL) and applied to a 400‐cm 2 stainless‐steel surface, then wiped by the coordinating body according to each laboratory's protocol. Wipe samples were distributed to individual laboratories, where blind analyses were conducted. Target criteria for accuracy and recovery were set at 70%–130% and 50%–130%, respectively. Of the 80 samples, 69 (86%) met accuracy targets, and 70 (88%) met recovery targets. Accuracy was often overestimated for the lowest concentrations of cyclophosphamide, etoposide, methotrexate, and paclitaxel by Laboratory A. Laboratory D showed low accuracy for paclitaxel at three lower concentrations. Among the 10 samples that did not meet recovery targets, all were below 50% and involved etoposide and paclitaxel. This ILC program demonstrates a viable method for evaluating laboratory performance in HMP detection, offering an external validation mechanism for surface wipe sampling methods. A future goal is to establish a global ILC program with a designated coordinating body for managing it effectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hazardous SubstancesEuropeHumansLaboratoriesPharmaceutical PreparationsMethotrexateCyclophosphamideQuality ControlOccupational ExposureGemcitabineEtoposide

Stichwörter der Autor:innen

analytical methodantineoplastic drugsquality controlsurface contaminationworkplace monitoring

Substanzen

Pharmaceutical PreparationsMethotrexateCyclophosphamideHazardous SubstancesGemcitabineEtoposide

Autor:innen und Institutionen

  • Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Department of Hospital Pharmacy, Haaglanden Medisch Centrum, The Hague, the Netherlands.
  • Department of Hospital Pharmacy, University Clinical Hospital, Poznan, Poland.
  • EPIUnit ITR, Institute of Public Health of the University Porto, University of Porto, Porto, Portugal.
  • LEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Porto, Portugal.
  • ALiCE-Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Porto, Portugal.

ORCID-Profile: Roland B van den Berg, Mónica S F Santos, Maria Francisca Portilha-Cunha, Ana R L Ribeiro, Luděk Bláha, Jochen Tuerk, Erik B Wilms, Mirjam Crul

Förderung

  • European Society of Oncology Pharmacy (ESOP)
  • Foundation for Science and Technology (FCT)
  • FCT/MCTES (PIDDAC)
  • Ministry of Education, Youth and Sports
  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

van den Berg, R. B., Korczowska, E., Santos, M. S. F., Portilha-Cunha, M. F., Ribeiro, A. R. L., Bláhová, L., Bláha, L., Eyser, C. V., Tuerk, J., van Rossen, R. C. J. M., Wilms, E. B., & Crul, M. (2025). Surface Wipe Sampling of Hazardous Medicinal Products: A European Interlaboratory Comparison Study. Drug Testing and Analysis. https://doi.org/10.1002/dta.3902

Vancouver

van den Berg RB, Korczowska E, Santos MSF, Portilha-Cunha MF, Ribeiro ARL, Bláhová L, et al. Surface Wipe Sampling of Hazardous Medicinal Products: A European Interlaboratory Comparison Study. Drug Testing and Analysis. 2025. doi:10.1002/dta.3902

BibTeX
@article{vandenBerg2025,
  author = {van den Berg, Roland B and Korczowska, Ewelina and Santos, Mónica S F and Portilha-Cunha, Maria Francisca and Ribeiro, Ana R L and Bláhová, Lucie and Bláha, Luděk and Eyser, Claudia Vom and Tuerk, Jochen and van Rossen, Richard C J M and Wilms, Erik B and Crul, Mirjam},
  title = {Surface Wipe Sampling of Hazardous Medicinal Products: A European Interlaboratory Comparison Study},
  journal = {Drug Testing and Analysis},
  year = {2025},
  doi = {10.1002/dta.3902}
}
Kostenlos starten →